Stay Informed – Updates on DCC-2618

On Monday, November 13^th, The Life Raft Group in collaboration with Deciphera Pharmaceuticals hosted a webcast which provided patients with an overview of the DCC-2618 GIST program, including enrollment updates from the ongoing phase 1 trial, reviewed key clinical data and provided details on the upcoming Phase 3 registration trial for the treatment of patients who have received at least 3 prior therapies. The webcast closed with a Q&A session.

Oliver Rosen, MD, Chief Medical Officer and Jama Pitman, VP Regulatory Affairs and Quality, both of Deciphera Pharmaceuticals, presented.

Oliver Rosen, MD Chief Medical Officer Deciphera Pharmaceuticals

Jama Pitman VP Regulatory Affairs & Quality Deciphera Pharmaceuticals